Bisphenol A (BPA) is an industrial chemical found in polycarbonate plastics and epoxy resins such as food-can linings, bottles, and dental fillings. The weak estrogenic activity of BPA ([@b26-ehp-117-645]; [@b39-ehp-117-645]) has raised questions as to its safety in humans. Human exposure to BPA is potentially widespread, and young children particularly are seen by regulatory authorities as a population of special concern \[[@b28-ehp-117-645]\]. Their susceptibility is based on their reduced capacity to eliminate xenobiotics in general ([@b21-ehp-117-645]) as well as their estimated higher weight-normalized daily exposure to BPA compared with adults \[[@b17-ehp-117-645]; [@b28-ehp-117-645]\]. Having a method to estimate the age dependence of internal BPA exposure is critical for developing a reasonable assessment of BPA risk to children.

In response to the identification of young children as a higher risk population, we investigated the exposure of children to BPA using physiologically based toxico kinetic (PBTK) modeling. PBTK models have been widely used in human health risk assessment to assess the potential internal human exposure to environmental compounds in the absence of direct human toxicokinetic data ([@b3-ehp-117-645]; [@b8-ehp-117-645]). Typically, toxicokinetic data from animals are used to build a compound-specific PBTK model that is then parameterized with information for humans (e.g., blood flows, organ volumes) ([@b8-ehp-117-645]; [@b53-ehp-117-645]). Although interspecies scaling represents the primary use of PBTK models, intraspecies scaling also represents a valuable means for assessing exposures in subpopulations ([@b16-ehp-117-645]). Pharmaco-/ toxicokinetic scaling for the purposes of both human health risk assessment and pharmaceutical drug development has focused on the pediatric subpopulation where physiologically based pharmacokinetic models are built for adult humans and scaled to children based on their physiologic differences ([@b5-ehp-117-645]; [@b14-ehp-117-645], [@b15-ehp-117-645]; [@b18-ehp-117-645]; [@b49-ehp-117-645]).

BPA is completely and rapidly absorbed from the gastrointestinal tract ([@b43-ehp-117-645]). Using an *ex vivo* method, [@b11-ehp-117-645] determined tissue:blood partition coefficients for human tissues after incubation with BPA. Because of the high lipophilicity of BPA, the adipose:blood partition coefficient (3.3) was two to three times greater than that of the other tested tissues (range, 0.9--1.82). Hepatic clearance of BPA to its glucuronidated metabolite, BPA-Glu, is rapid and complete, and BPA-Glu is the predominant substance found in plasma ([@b43-ehp-117-645]). Urinary excretion is the only route of elimination for BPA-Glu ([@b43-ehp-117-645]). The toxicokinetics of these substances have been studied only in adults. Toxicokinetic scaling to children using PBTK models remains the only means to reasonably assess relative internal BPA exposures.

The objectives of this modeling study were to estimate the differences in the average steady-state dose-normalized BPA plasma and urinary concentrations between adults and children \< 2 years of age after BPA administration and to determine the expected average steady-state plasma concentrations of BPA and BPA-Glu in young children after typical feeding scenarios.

Materials and Methods
=====================

PBTK Model Structure and Software
---------------------------------

In this study we used a nested coupled PBTK structure consisting of a BPA submodel coupled to a BPA-Glu submodel ([Figure 1](#f1-ehp-117-645){ref-type="fig"}). We used PK-Sim software (version 4.0; Bayer Technology Services GmbH, Leverkusen, Germany) to generate each individual sub-model. [Figure 1](#f1-ehp-117-645){ref-type="fig"} graphically presents the PBTK model structure implemented in PK-Sim \[presented by [@b44-ehp-117-645]; [@b46-ehp-117-645], [@b45-ehp-117-645]; described by differential and algebraic equations in the Supplemental Material (<http://www.ehponline.org/members/2008/0800073/suppl.pdf>)\]. The model includes 15 organs as well as arterial, venous, and portal blood compartments. The organs are connected via blood flows, and the circulation system is closed via the lung. We coupled the sub-models on export to MoBi (version 2.0; Bayer Technology Services GmbH), a software package for the mechanistic and dynamic modeling of biologic processes and drug action. We linked the two submodels such that the hepatic clearance of BPA was the only source function for the BPA-Glu submodel, where the process was defined in the liver.

PBTK Model Parameterization
---------------------------

### BPA and BPA-Glu physicochemistry

[Table 1](#t1-ehp-117-645){ref-type="table"} presents physicochemical and physiologic parameters of BPA and BPA-Glu.

### Anatomical and physiologic parameters

We previously published the body weight, height, blood flows, and organ volumes for children and adults, as used in the PK-Sim software ([@b15-ehp-117-645]). [Table 2](#t2-ehp-117-645){ref-type="table"} presents these parameter values as used in the pediatric and adult models for this study.

### Absorption

The oral absorption model is that of [@b47-ehp-117-645], [@b48-ehp-117-645], and this model provided BPA input to the portal vein. We considered scaling the gastrointestinal parameters of gastrointestinal geometry, gastric emptying time, intestinal permeability, gastric and intestinal pH, small intestinal transit time, and intestinal surface area to children between 0 and 2 years of age. However, because of the high absorbed fraction (*f~a~* = 1) of orally administered BPA, these various inputs did not make a life-stage difference. As a result, all simulations used an *f~a~*value of 1.

### Distribution

We used the algorithms of [@b33-ehp-117-645] and [@b31-ehp-117-645], [@b32-ehp-117-645] to estimate tissue:plasma partition coefficients. Required input data were the fraction unbound in plasma, lipophilicity, and acid/base properties. [Table 1](#t1-ehp-117-645){ref-type="table"} presents these input data for BPA and BPA-Glu. We slightly modified the [@b33-ehp-117-645] and [@b31-ehp-117-645], [@b32-ehp-117-645] algorithm for children with respect to the interplay between neutral lipids and extracellular water. The volume fraction lipids in adipose tissue increases with age ([@b4-ehp-117-645]) due to an adipocyte generation and cell volume growth ([@b7-ehp-117-645]; [@b36-ehp-117-645]; [@b37-ehp-117-645]). A relationship between the volume fraction lipids and interstitial space with age has been previously developed to adjust the adipose:plasma partition coefficient ([@b15-ehp-117-645]). We similarly altered the [@b33-ehp-117-645] and [@b31-ehp-117-645], [@b32-ehp-117-645] algorithm through the interplay between the volume fraction neutral lipids and extracellular water for children. Permeability × surface area (PS) products define the rate of organ/tissue uptake and are estimated in PK-Sim. PS scaling to children used the following allometric function:
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where *V* is the volume of the tissue.

### Elimination

#### BPA clearance (CL~BPA_liver~)

We assumed that 100% of the elimination of BPA was attributable to metabolism to its glucuronidated metabolite, BPA-Glu. This is supported by [@b43-ehp-117-645], who determined that recovery of an isotope of BPA-Glu in plasma after human trials was equivalent to that of total BPA after addition of a glucuronidase. The enzyme responsible for this has not been directly assessed in humans. In rats, the responsible rat-specific isozyme is UDP-glucuronosyltransferase (UGT) 2B1 (UGT2B1) ([@b51-ehp-117-645]). This rat-specific isozyme has a sequence and a substrate specificity similar to the human UGT2B7 isozyme. Using full-length rat UGT2B1 as a probe in a human cDNA library, one of two full-length clones was found to be UGT2B7 ([@b10-ehp-117-645]), as characterized by [@b23-ehp-117-645]. [@b35-ehp-117-645] demonstrated that dog UGT2B31, rat UGT2B1, and human UGT2B7 display similar substrate specificities, and that dog UGT2B31 had sequence alignments that were 75% and 73% identical to human UGT2B7 and rat UGT2B1. Using morphine, a known UGT2B7 substrate, as a probe, [@b30-ehp-117-645] showed morphine glucuronidation at the 3-position by rat UGT2B1 with high velocity, a result confirmed by [@b35-ehp-117-645] with the addition of minute observed amounts the 6-*O*-glucuronide. [@b10-ehp-117-645] have shown conclusively that human UGT2B7 can catalyze morphine glucuronidation at both the 3- and 6-positions, but the isozyme was approximately 10-fold more efficient at forming the 3-*O*-glucuronide. Another study examining the UGT responsible for diclofenac glucuronidation in humans found that rat UGT2B1 and human UGT2B7 both catalyzed this reaction with similar affinities ([@b24-ehp-117-645]). Based on the evidence of UGT2B1 and UGT2B7 sequence similarities and substrate overlaps, we considered UGT2B7 the enzyme responsible for BPA glucuronidation and thus used the enzyme ontogeny of UGT2B7 to scale the intrinsic clearance of BPA to BPA-Glu from adults to children. UGT2B7 activity in term neonates is only 5% that of adults, increases to 30% by 3 months of age, and reaches adult levels by 1 year of age ([@b14-ehp-117-645]).

We described the method of scaling clearance from adults to children ([@b14-ehp-117-645]). In brief, for hepatically cleared compounds, the plasma clearance (CL*~H~*; milliters per minute) from adults is converted to an intrinsic clearance (CL~int~; milliters per minute) using the well-stirred model (Equation 2) and physiologic information of liver blood flow (*Q~H~*; mL/min) and the fraction unbound in plasma (*f~u~*):
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Clearance is then normalized to liver weight (milliters per minute/grams liver) and multiplied by the percentage of activity relevant to the age of the child to derive a liver weight--normalized intrinsic clearance for the child. Plasma clearances for children are derived by rearrangement of Equation 2 and by using the age-specific liver weight, blood flow, and estimated *f~u~* as derived using the method of [@b27-ehp-117-645]. This method adjusts the *f~u~* in adults to children based on the age dependence of albumin concentrations in plasma ([@b27-ehp-117-645]).

#### BPA-Glu clearance (CL~BPA-Glu_kidney~)

Urinary excretion is 100% responsible for BPA-Glu clearance in humans ([@b43-ehp-117-645]). We optimized plasma CL~BPA-Glu_kidney~ during the development of the adult coupled model and compared this with values derived from [@b43-ehp-117-645]. We also compared the estimated time course of BPA urinary excretion with that from [@b43-ehp-117-645]. Allometric relationships as described by [@b19-ehp-117-645] and modified slightly by [@b14-ehp-117-645] formed the basis for scaling the age dependence of CL~BPA-Glu_kidney~.

We used the following equation to calculate the total BPA (BPA + BPA-Glu) average urinary concentration at steady state (*C*~BPA_urine~):
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where *M*~BPA~ is the mass of BPA ingested per day, *f~e~* is the fraction excreted to urine, and *V*~urine~ is the volume of urine produced in 1 day. *f~e~* is 1 because 100% of the BPA dose is converted to BPA-Glu, and 100% of BPA-Glu is excreted to urine, results observed by [@b43-ehp-117-645]. A linear interpolation of *V*~urine~, as taken from the International Commission on Radiological Protection ([@b22-ehp-117-645]), provided values for newborns and for 3-month-, 6-month-, 1-year-, 2-year-, and 30-year-olds of 300, 320, 350, 400, 425, and 1,600 (adult male) mL/day, respectively. [@b25-ehp-117-645] used this equation in a rearranged form to calculate the daily BPA exposure from urinary concentrations and daily urine volume.

Development of the Adult BPA--BPA-Glu Coupled Model
---------------------------------------------------

We parameterized the BPA and BPA-Glu models in PK-Sim for an average 30-year-old male of 73 kg and 176 cm ([@b22-ehp-117-645]). We used the experimental plasma concentration time data of BPA-Glu after BPA administration from [@b43-ehp-117-645] to parameterize the unknown data of CL~BPA_liver~, BPA-Glu lipophilicity (used for calculation of tissue:plasma partition coefficients), and CL~BPA-Glu_kidney~. We simulated a BPA oral dose of 5 mg ([@b43-ehp-117-645]). We set CL~BPA_liver~ for this male at the lowest integer that maintained the BPA concentrations lower than the 10-nM limit of detection from the [@b43-ehp-117-645] study. We then coupled the BPA and BPA-Glu submodels in MoBi to reflect the metabolism process. The change of intracellular concentration due to BPA metabolism to BPA-Glu (CL~BPA_liver~) is calculated as (CL~BPA_liver~ × *C*~cell_liver_BPA~ × *f*~u_BPA~/*K*~liver_BPA~)/*V*~cell_liver~, where *C*~cell_liver_BPA~ is the concentration of BPA in the liver intra-cellular space, *f~u~*~\_BPA~ is the unbound fraction of BPA in plasma, *K*~liver_BPA~ is the liver:plasma partition coefficient, and *V*~cell_liver~ is the intracellular volume of the liver \[see Supplemental Material for full differential equations (<http://www.ehponline.org/members/2008/0800073/suppl.pdf>)\].

The only unknown parameters at this point were the lipophilicity of BPA-Glu and CL~BPA-Glu_kidney~. We optimized these parameters using the plasma concentration--time data of BPA-Glu for all subjects studied by [@b43-ehp-117-645]. The objective function was the root mean squared error measured as the root of the squared difference between the predicted and observed plasma concentrations for both compounds. For optimization, we used the Mobi-Toolbox for MatLab (Bayer Technology Services GmbH) and the MatLab \[version 7 (R14); MathWorks Inc., Natick, MA, USA\] fminsearch optimization routine without constraints. We used the optimized BPA-Glu lipophilicity in all simulations for children as a means to predict partition coefficients. We scaled the optimized adult CL~BPA-Glu_kidney~ to children as previously described. During the scaling procedure and simulations in children, we allowed no changes to the coupled model structure.

Scaling the Adult Coupled Model to Children
-------------------------------------------

Once we set the adult model of BPA and BPA-Glu, we made changes to scale the model to children. We used the following age-specific parameters: weight, height, organ volumes, blood flows, volume fraction of fat in adipose tissue, tissue:plasma partition coefficients, PS, CL~BPA_liver~, CL~BPA-Glu_kidney~, and *f~u~*.

Simulations
-----------

First, we completed simulations after a BPA application of 1 μg/kg once per day to demonstrate the expected differences in the average dose-normalized plasma concentrations at steady state of BPA and BPA-Glu in adults and young children (0--2 years of age). Second, we used published environmental exposure data ([@b17-ehp-117-645]) ([Table 3](#t3-ehp-117-645){ref-type="table"}) to estimate the average plasma concentration at steady state in children and adults under typical feeding scenarios. Because [@b17-ehp-117-645] exposure scenarios did not include breast-fed newborns, we included this group by calculating exposure based on average daily breast milk intake and total BPA concentration in breast milk. The average daily breast milk intake is 13 g/kg on the first day of life, increases gradually 98 g/kg on day 3, and reaches a relatively constant level of 155 g/kg from day 5 ([@b9-ehp-117-645]). In the early days, using the highest concentration of free plus conjugated BPA from [@b50-ehp-117-645], which is 1.62 μg/L, 95% of which was free BPA, the newborn (postnatal age = 5 days; 3.5 kg) would receive 0.88 μg of BPA per day, assuming that all conjugated BPA is cleaved in the gastrointestinal tract. We also simulated this exposure scenario. We took average concentrations at steady state as the average concentration over one dosing interval after the system reached steady state. After simulations of a 1-μg/kg/day intravenous (iv) bolus at all ages, we calculated BPA bioavailability (*F*) as
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where *AUC* is the area under the simulated plasma concentration time curve for an iv or peroral (po) BPA dose.

Sensitivity Analysis
--------------------

We used local sensitivity analysis here to pri-oritize the impact of the input parameters on the outcome of interest: the average steady-state plasma concentration (*C*~avg_ss~). We used its simplest form where an input parameter value (*P*~in~) is changed by 1% and the relative change in outcome is calculated when all other input parameters are fixed:
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We performed all sensitivity analyses based on a BPA dose of 1 μg/kg/day for an adult. We used sensitivity analyses to assess the variation of both BPA and BPA-Glu organ/tissue volumes (18), organ blood flows (14), hematocrit (1), *f~u~* (1), organ:plasma partition coefficients (15), red blood cell partition coefficient (1), red blood cell permeability (1), organ PS (15), organ-specific PS~rbc~ (18), intrinsic hepatic clearance of BPA (1), and intrinsic kidney clearance of BPA-Glu (1) on *C*~avg_ss~ of both BPA and BPA-Glu.

Results
=======

Adult BPA--BPA-Glu coupled model
--------------------------------

The plasma CL~BPA_liver~ required to keep the first data point (51 min) below the limit of detection of 10 nM ([@b43-ehp-117-645]) was 21 mL/min/kg. This corresponded to 88% of liver blood flow. The optimized plasma clearance (CL~BPA-Glu_kidney~) for the urinary excretion of BPA-Glu and the BPA-Glu lipophilicity were 1.82 mL/min/kg and −0.05, respectively. CL~BPA-Glu_kidney~ was equal to that derived by [@b43-ehp-117-645]. At 12 and 24 hr, the estimated dose excreted to urine was 83% and 91%, compared with 91% and 94% as observed by [@b43-ehp-117-645], respectively. [Table 4](#t4-ehp-117-645){ref-type="table"} presents the estimated tissue:plasma partition coefficients for BPA and BPA-Glu for adults and children. [Table 5](#t5-ehp-117-645){ref-type="table"} presents the PS products for adults. [Figure 2](#f2-ehp-117-645){ref-type="fig"} presents the optimized plasma concentration time profiles for BPA and BPA-Glu in adults.

Simulations in children and adults
----------------------------------

At all ages, 100% of the applied BPA dose was modeled as absorbed to the portal vein (*f~a~* = 1), although there was an increase in the efficiency of first-pass metabolism with increasing age. Bioavailability (*F*) in newborns and 3-month-, 6-month-, 1.5-year-olds, and adults was 88%, 48%, 32%, 23%, and 18%. In all simulations, BPA and BPA-Glu steady state was reached within the first 48 hr. [Figure 3](#f3-ehp-117-645){ref-type="fig"} presents average plasma concentrations at steady state and urinary concentrations for children and adults after BPA administration of 1 μg/kg/day. [Figure 4](#f4-ehp-117-645){ref-type="fig"} presents the average plasma concentrations at steady state of BPA and BPA-Glu as well as the expected urinary concentrations after typical exposure scenarios in children and adults.

Sensitivity analysis
--------------------

Values \> 1 were of interest in that they identified input parameters that had potential to greatly affect *C*~avg_ss~. No varied parameter in the BPA model produced a value \> 1, with respect to BPA average steady-state concentrations, although values to note (\> 0.1) were *f~u~* (0.98), hematocrit (0.16), and intrinsic hepatic clearance (0.89). No varied parameter in the BPA model, with respect to BPA-Glu average steady-state concentrations, produced a value greater than 1. No parameter in the BPA-Glu model, with respect to BPA-Glu average steady-state concentrations, produced a value \> 1, although a value to note was intrinsic renal clearance (0.80).

Discussion
==========

Existing PBTK models of BPA and/or BPA-Glu were not appropriate for use in this scaling study. [@b41-ehp-117-645] described a partial PBTK model consisting of five compartments for BPA and a one-compartment model for BPA-Glu. [@b41-ehp-117-645] parameterized this rat model using *in vivo* data from rats after BPA exposure with subsequent scaling to humans. The lumped compartments in the model did not provide an appropriate structure that could account for the relevant physiologic inputs that are required to reliably scale from adult humans to children. This necessitated the use of another model. [@b34-ehp-117-645] adopted a more whole-body PBTK approach and used *in vivo* data from rats for parameterization. Their model focused on BPA, not BPA-Glu. Further, they measured tissue:plasma partition coefficients 3--4 hr after initial exposure, which for a lipophilic compound such as BPA would not be sufficient to reach steady state. The result was a partition coefficient in adipose tissue that was lower than all other organs as well as blood, a result in stark contrast to data from [@b11-ehp-117-645], who demonstrated in *ex vivo* experiments that the adipose:plasma partition coefficient was two to three times higher than all other tested tissues. Although in rat this value may not be particularly important for describing the kinetics of a lipophilic compound, because only approximately 4% of body weight is adipose tissue, humans have approximately 15--30% of body weight as adipose tissue, so this value is greatly influential. [Table 4](#t4-ehp-117-645){ref-type="table"} presents experimental tissue:plasma partition coefficients from various experimental studies ([@b11-ehp-117-645]; [@b34-ehp-117-645]; [@b52-ehp-117-645]). The estimated partition coefficients from the [@b33-ehp-117-645] and [@b31-ehp-117-645], [@b32-ehp-117-645] algorithm were within range of the experimental values and deemed reasonable for use in this model. Based on the above limitations in existing BPA models, we used a whole-body PBTK model previously used for scaling drug pharmacokinetics from adults to children ([@b15-ehp-117-645]). This model has been shown to be physiologically consistent in adults and in children down to newborns. Some examples of this consistency include the following: sum of blood flows = cardiac output; sum of splanchnic organs = portal vein flow; total body water, lipid, and protein is age dependent and consistent with the literature; and addition of blood pool volumes and vascular volume for each organ = total blood content ([@b15-ehp-117-645]). With the integration of the [@b33-ehp-117-645] and [@b31-ehp-117-645], [@b32-ehp-117-645] algorithm for partition coefficient estimation, and the gastrointestinal tract model of [@b47-ehp-117-645], [@b48-ehp-117-645], all relevant physiology could be accounted in order to scale BPA and BPA-Glu from adults to children.

Optimization of the BPA-Glu lipophilicity parameter as a means to estimate tissue:plasma partition coefficients from the [@b33-ehp-117-645] and [@b31-ehp-117-645], [@b32-ehp-117-645] algorithm resulted in a BPA-Glu distribution volume that was equivalent to that from the [@b43-ehp-117-645] study (0.43 L/kg). BPA-Glu partition coefficients were, on average, 10 times lower than those of BPA. This is reasonable because glucuronidation and, in general, phase II metabolism aim at increasing water solubility and thus, in the absence of specific binding, results in lower partition coefficients than for the parent compound.

Young children are physiologically different from adults, and this could be considered in the PBTK model that we developed for BPA and BPA-Glu. The activity of many hepatic enzymes is lower at birth, and the activity increase with age occurs at an enzyme-specific rate ([@b14-ehp-117-645]). In the case of BPA, we considered UGT2B7 the enzyme responsible for BPA hepatic clearance, where newborns had only 5% of the enzymatic activity of the adult liver. This was also responsible for a relative lack of first-pass effect in newborns (*F* = 88%) and subsequently a bioavailability decrease with age. Taken with a distribution change over age (↑ *f~u~*, ↓ *K*~adipose~), the dose-normalized BPA plasma concentrations at steady state were a maximum of 11 times higher than that in adults. As enzyme activity reached that of adults at 1 year of age, the dose-normalized BPA plasma concentrations at this age were lower than in adults because of a higher weight-normalized plasma clearance. This phenomenon has been documented previously ([@b14-ehp-117-645]). It is of interest that this pediatric PBTK model has been previously used to scale the pharmacokinetics of the UGT2B7 substrate morphine to children with acceptable accuracy ([@b15-ehp-117-645]). Adult morphine plasma clearance, primarily due to hepatic UGT2B7 activity, is 20.5 mL/min/kg for adults ([@b14-ehp-117-645]), a clearance similar to that defined for BPA UGT2B7 plasma clearance (21 mL/ min/kg). Thus, the scaling of BPA clearance follows closely with that of morphine.

It is important here to note the limitations of the model with respect to clearance scaling. We generated the BPA plasma clearance in adults based on maintenance of the BPA plasma concentrations that were lower that the limit of detection in the [@b43-ehp-117-645] study. This value of 21 mL/min/kg represented the lower bound of clearance because we could still meet the criteria given a higher clearance up to a blood flow limitation at around 24 mL/min/kg, with little change in BPA-Glu concentrations (average BPA-Glu concentrations not sensitive to hepatic intrinsic clearance in the BPA model). For the purposes of clearance scaling, our approach to using the lower bound represented the "worst-case scenario" when scaling to children. Scaling clearance for a blood flow limited clearance compound is not possible because intrinsic clearance approaches infinity when blood flow equals blood clearance. In this case, the activity of the enzyme is unknown, and the clearance in the child could reach 100% of hepatic blood flow despite a reduction in intrinsic enzyme activity. Thus, the method we used to generate an adult clearance was the most conservative with respect to pediatric clearance scaling because it represented a worst-case scenario. Further, when clearance scaling to young children, there exists uncertainty when using enzyme activity ontogeny data ([@b6-ehp-117-645]) because a period of high interindividual variability is present between the postnatal onset and expression increase of hepatic enzymes ([@b20-ehp-117-645]). This has been demonstrated for glucuronidating enzymes ([@b40-ehp-117-645]) and is expected to be relevant to this discussion regarding BPA. Therefore, the clearance scaling method is built on average *in vitro* activity levels and is not conservative in predicting plasma concentrations in the most developmentally delayed pediatric liver.

We performed a sensitivity analysis to assess the relative importance of the input parameters in affecting the average steady-state BPA concentrations. We performed only a local sensitivity analysis here, so any significant parameter correlations would not be revealed using this method. We found that BPA and BPA-Glu concentrations were not hypersensitive to any one parameter in the model. Of interest to BPA concentrations were the fraction unbound in plasma (0.98) and the hepatic intrinsic clearance of BPA (0.89). For the BPA-Glu concentrations, the parameter renal intrinsic clearance of BPA-Glu (0.80) was of interest. To be confident in our scaled model for children, ensuring the accuracy of these parameters for children is important. We scaled the fraction unbound in plasma from adults based on the method of [@b27-ehp-117-645], a method demonstrated to be useful for a wide variety of drugs within a varied binding range. This scales the binding fraction based on the age-dependent levels of the binding protein (albumin) in blood. In the absence of experimental data, this algorithm represents the best means of scaling the unbound fraction to children. The hepatic intrinsic clearance, as previously discussed, is not readily discernable from the experimental data currently available. For the purposes of clearance scaling, although UGT2B7 ontogeny has been widely examined ([@b1-ehp-117-645]; [@b13-ehp-117-645]; [@b14-ehp-117-645]), the actual adult intrinsic clearance is a difficult parameter to measure given the lack of sensitive analytical techniques for BPA and the borderline blood flow limitation of clearance in the adult. Given the relative importance of this parameter on the outcome of this model, its uncertainty may denigrate the modeling effort to a screening level exercise as opposed to a definitive study and suggests the need to determine adult BPA clearance with certainty. We scaled the renal clearance of BPA-Glu based on the method of [@b19-ehp-117-645], as modified for children \< 2 days of age by [@b14-ehp-117-645]. This method represents the most widely used renal clearance scaling algorithm ([@b2-ehp-117-645]), and we expect that it accurately predicted renal BPA-Glu clearance in children \< 2 years of age.

[@b42-ehp-117-645] measured plasma concentrations in 19 randomly chosen, unintentionally exposed individuals. Plasma concentrations of total BPA (after glucuronidase treatment) in adults were always below the limit of detection of 0.5 μg/L ([@b42-ehp-117-645]). The average steady-state plasma concentration of total BPA in adults after a typical exposure of 1.5 μg/kg/day was 0.58 μg/L ([Figure 4](#f4-ehp-117-645){ref-type="fig"}), which suggests that this estimated exposure value is higher than that of the population studied by [@b42-ehp-117-645]. We took typical BPA exposures for adults and children from an [@b17-ehp-117-645], although other exposure scenarios have been documented ([@b25-ehp-117-645]; [@b28-ehp-117-645]). Because only using passive diffusion processes explain the kinetics and because linear BPA and BPA-Glu clearance are assumed, plasma concentrations can be scaled directly with daily exposure dose. This is also the case with urinary concentrations. Using the exposure scenarios of EFSA and assuming conservative migration behavior of BPA from food containers ([@b17-ehp-117-645]), BPA average plasma concentrations at steady state in 3-month-olds (4 μg/kg/day) and 6-month-olds (8.3 μg/ kg/day) were approximately five times greater than those in adults. Breast-fed newborns and 3-month-olds, under typical exposure scenarios, had concentrations 1.8-fold and 0.26-fold, respectively, that in adults ([Figure 4](#f4-ehp-117-645){ref-type="fig"}).

Because of the relative ease of urine sampling compared with blood sampling, the greatest body of exposure literature is based on urinary concentrations of BPA after sampling of unintentionally exposed individuals. The literature contains little information on children. Based on urinary BPA concentrations, there was a tendency toward higher calculated BPA intakes and urinary concentrations in children and adolescents 6--19 years of age ([@b25-ehp-117-645]) compared with adults. We showed higher urinary concentrations in young children than in adults ([Figure 4](#f4-ehp-117-645){ref-type="fig"}) under typical exposure scenarios, although our urinary concentrations were approximately 25 times higher than those found in adults in both the [@b25-ehp-117-645] and [@b12-ehp-117-645] studies, leading to doubt as to how typical the EFSA exposure scenarios really are. Although [@b12-ehp-117-645] suggested that there is an uncertainty of approximately one order of magnitude when using single spot urine samples to estimate total daily intake by an individual, as was the case in the [@b25-ehp-117-645] and [@b12-ehp-117-645] studies, the [@b17-ehp-117-645] exposure scenarios are apparently high-end estimates of BPA intake for adults and likely also for young children. Determining actual daily intakes in children \< 6 years of age, as recommended by [@b25-ehp-117-645], is important because real exposures in this age group are unknown. Once urinary concentrations are known, back-calculations can be made to estimate daily exposures, and then, using the PBTK model, circulating BPA plasma concentrations may be estimated. This can be of interest when assessing the risks associated with BPA exposure in children. Urinary concentrations at steady state can be used to back-calculate to daily exposures ([@b25-ehp-117-645]), although this does not indicate the internal BPA load. Input of the estimated daily exposure into the PBTK model could be used to estimate the circulating BPA concentration and/or tissue concentrations of interest. In this second step, however, uncertainly exists such that there is interplay between plasma concentrations and enzyme activity (for BPA) or urinary clearance (for BPA-Glu) that cannot be directly known simply from a urine sample. Reducing this uncertainty would require direct validation of the PBTK model in young children. This validation would come in the form of blood concentrations of BPA and BPA-Glu in a number of young children. Once acceptance and/or modification of the model is completed, we can extrapolate among ages, doses, and disease states as well as estimate tissue loads with greater confidence.

In summary, we developed a PBTK coupled model system for BPA and its metabolite, BPA-Glu, in adults and scaled to children based on age-dependent physiologic parameters. Because of low UGT2B7 activity, BPA plasma concentrations could be approximately 11 times greater in newborns than in adults exposed to the same weight-normalized dose. An increase in age to 3 months lowers this ratio to 2, although exposure through food can be greater in this age group than in adults ([@b17-ehp-117-645]; [@b28-ehp-117-645]). When considering different feeding scenarios, the highest and lowest BPA concentrations differed by a factor of 55. Thus, age-dependent differences may be substantial but cannot be absolutely quantified because of a need for both clearer understanding of the *in situ* hepatic intrinsic BPA clearance in the adult and urinary concentrations in children \< 6 years of age to define daily BPA intake. As a worst-case scenario, these findings suggest that the typical intraspecies uncertainty/safety factor of 10 commonly applied to a threshold dose ([@b29-ehp-117-645]) is just sufficiently protective of very young children who have average or above average glucuronidation capacity. EFSA derived a tolerable daily intake of 50 μg (BPA)/kg based on the application of a 100-fold uncertainly factor (10 for interspecies differences and 10 for interindividual differences) to a no observable adverse effect level of 5 mg/kg/day in rats. It is apparent from this modeling study that newborns with less than average glucuronidation capacity may not be adequately considered based on a factor of 10 to account for human variability in BPA toxicokinetics.

Supplemental Material is available online at <http://www.ehponline.org/members/2008/0800073/suppl.pdf>
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![Schematic of the PBTK model structure consisting of BPA and BPA-Glu submodels. Input of BPA was to the stomach, thus simulating oral administration. Input of BPA-Glu was the hepatic metabolism of BPA to BPA-Glu in the liver.](ehp-117-645f1){#f1-ehp-117-645}

![Simulated BPA and BPA-Glu plasma concentration time profile for an adult male after oral administration of BPA. Observed data taken from [@b43-ehp-117-645].](ehp-117-645f2){#f2-ehp-117-645}

![Estimated BPA and BPA-Glu average steady-state plasma concentrations in children and adults after a 1-μg/kg/day oral administration of BPA. Total BPA = BPA + BPA-Glu urinary concentration.](ehp-117-645f3){#f3-ehp-117-645}

![Estimated BPA and BPA-Glu average steady-state plasma concentrations in children and adults after an oral administration of BPA using daily exposures (values in parentheses in μg/kg) taken from [@b17-ehp-117-645] or, for newborns, estimated from breast milk intake and total BPA breast milk concentration. Total BPA = BPA + BPA-Glu urinary concentration.](ehp-117-645f4){#f4-ehp-117-645}

###### 

BPA and BPA-Glu compound properties.

  Property                           BPA                                                                     BPA-Glu
  ---------------------------------- ----------------------------------------------------------------------- -----------------------------------------------------
  Lipophilicity                      Log *K*~ow~ = 3.4 ([@b38-ehp-117-645])                                  −0.05[a](#tfn2-ehp-117-645){ref-type="table-fn"}
  Molecular weight (g/mol)           228; 244[b](#tfn3-ehp-117-645){ref-type="table-fn"}                     404; 418[b](#tfn3-ehp-117-645){ref-type="table-fn"}
  p*K*~a~                            9.6, 10.2 ([@b38-ehp-117-645])                                          Used same as for BPA
  Water solubility (mg/L)            120--300 ([@b38-ehp-117-645])                                           NA
  Blood:plasma ratio                 1.05[c](#tfn4-ehp-117-645){ref-type="table-fn"}                         0.83[c](#tfn4-ehp-117-645){ref-type="table-fn"}
  Plasma protein binding             *K~d~* = 100 nmol/mL ([@b11-ehp-117-645]) *f~u~* = 3.5%                 *f~u~* = 95% (deduced from [@b43-ehp-117-645])
  Intestinal permeability (P~int~)   2.8 × 10^−5^; 2.6 × 10^−5^[a](#tfn2-ehp-117-645){ref-type="table-fn"}   NA

Abbreviations: NA, not applicable.

Optimized value using experimental plasma concentration time data from [@b43-ehp-117-645].

Relevant for [@b43-ehp-117-645] simulations because they administered d16-BPA. The first printed value was used for all simulations in children.

Estimated in PK-Sim. Experimental BPA blood:serum ratio in rats is 1.1 ([@b34-ehp-117-645]).

###### 

Parameter values of body weight, body height, and hematocrit as well as organ or tissue volumes (g) and organ blood flows (mL/min) as used in the adult and pediatric PBTK models.

                     Age                                                                    
  ------------------ --------- ---------- ----------- ----------- ----------- ------------- --------------
  Adipose            906/30    1,758/55   2,596/67    3,666/60    3,999/75    4,245/90      14,868/325
  Body height (cm)   51        58         65          76          82          88            176
  Body weight (kg)   3.5       5.4        7.2         10.0        11.7        13.0          73.0
  Bone               452/30    677/44     922/53      1,377/60    1,696/80    1,940/97      11,818/324
  Brain              395/180   576/306    754/448     988/700     1,077/898   1,151/1,095   1,508/780
  Gonads             1.1/0.3   1.3/0.4    1.5/0.5     1.8/0.6     2/0.8       2/1           40/3
  Hematocrit         0.58      0.35       0.36        0.36        0.36        0.36          0.47
  Heart              28/24     38/34      48/40       66/48       80/65       90/80         417/260
  Kidneys            38/110    55/160     72/192      103/230     126/311     141/378       438/1,325
  Large intestine    21/24     30/35      40/42       58/48       72/63       84/76         412/260
  Liver              185/39    256/55     325/65      452/78      552/106     627/131       2,357/423
  Lung               84/588    119/906    153/1,167   216/1,536   264/2,016   295/245       1,294/6,106
  Muscle             968/31    1,311/45   1,628/55    2,215/72    2,767/95    3,287/116     32,338/1,106
  Pancreas           9/6       13/9       19/11       28/12       35/16       39/20         190/65
  Skin               216/30    281/42     334/49      417/60      483/79      529/95        3,761/325
  Small intestine    36/60     52/86      68/103      99/120      125/160     148/194       724/650
  Spleen             17/18     25/26      33/32       49/36       60/49       68/60         243/195
  Stomach            8/6       12/9       16/10       23/12       29/16       35/19         168/65
  Venous blood       38        48         55          68          85          101           691
  Arterial blood     38        48         55          68          85          101           691
  Portal blood       57        72         83          102         127         151           1,037

Double values are organ weight (g)/organ blood flow (mL/min).

Volume represents "wet weight" where vascular volume is added to organ volume as given in ICRP (2002).

###### 

Estimated BPA exposure scenarios for infants \> 3 months of age taken from the [@b17-ehp-117-645] report and breast-fed newborn exposure as calculated from [@b9-ehp-117-645] and [@b50-ehp-117-645].

  Age         Food/beverages consumed                                                Exposure/day (μg/kg)                                                                               No. of feedings/day
  ----------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------
  Newborn     Breast-fed only                                                        0.25                                                                                               8
  3 months    Breast-fed only                                                        0.2                                                                                                8
  3 months    Formula fed with polycarbonate bottle                                  4.0[a](#tfn7-ehp-117-645){ref-type="table-fn"} (11.0[b](#tfn8-ehp-117-645){ref-type="table-fn"})   8
  6 months    Formula fed with polycarbonate bottle and commercial foods/beverages   8.3[a](#tfn7-ehp-117-645){ref-type="table-fn"} (13.0[b](#tfn8-ehp-117-645){ref-type="table-fn"})   6
  1.5 years   2 kg commercial foods/beverages                                        5.3                                                                                                6
  Adult       3 kg commercial foods/beverages                                        1.5                                                                                                4

Based on a conservative value for migration of BPA into infant formula ([@b17-ehp-117-645]).

Based on an upper value for migration of BPA into infant formula ([@b17-ehp-117-645]).

###### 

The ratio of estimated plasma unbound fraction in children (*f~u~*~,child~) to the reported unbound fraction in adults (*f~u~*~,adult~) and the estimated tissue:plasma partition coefficients for BPA and BPA-Glu.

  Parameter                             BPA[a](#tfn9-ehp-117-645){ref-type="table-fn"}   BPA-Glu[a](#tfn9-ehp-117-645){ref-type="table-fn"}   [@b34-ehp-117-645][b](#tfn10-ehp-117-645){ref-type="table-fn"}   [@b52-ehp-117-645]   [@b11-ehp-117-645][c](#tfn11-ehp-117-645){ref-type="table-fn"}
  ------------------------------------- ------------------------------------------------ ---------------------------------------------------- ---------------------------------------------------------------- -------------------- ----------------------------------------------------------------
  *f~u~*~,child~/*f~u~*~,adult~ (age)                                                                                                                                                                                               
   Term neonate                         1.29                                             1.01                                                                                                                                       
    3 months                            1.28                                             1.01                                                                                                                                       
    6 months                            1.27                                             1.01                                                                                                                                       
    1 year                              1.25                                             1.01                                                                                                                                       
    2 years                             1.23                                             1.01                                                                                                                                       
  Adipose (age)                                                                                                                                                                                                                     
   Term neonate                         3.8                                              0.59                                                                                                                                       
    3 months                            5.6                                              0.43                                                                                                                                       
    6 months                            5.7                                              0.42                                                                                                                                       
    1 year                              5.8                                              0.41                                                                                                                                       
    2 years                             5.9                                              0.40                                                                                                                                       
    30 years                            8.3                                              0.18                                                 0.7 ± 0.6                                                                             3.31 ± 0.17
  Bone                                  1.7                                              0.42                                                                                                                                       
  Brain                                 3.6                                              0.75                                                 4.4 ± 0.6                                                        0.75                 1.06 ± 0.09
  Gonads                                0.79                                             0.83                                                 3.4 ± 0.5                                                        2.8                  
  Heart                                 1.6                                              0.57                                                 3.4 ± 1.0                                                        3.3                  
  Kidneys                               1.8                                              0.68                                                 4.4 ± 0.7                                                        4.9                  1.35 ± 0.17
  Large intestine                       3.8                                              0.75                                                                                                                  4.1                  
  Small intestine                       3.8                                              0.75                                                 45.96 ± 3.2                                                                           
  Stomach                               3.8                                              0.75                                                 4.6 ± 0.9                                                        4.1                  
  Liver                                 1.9                                              0.65                                                 5.7 ± 2.2                                                        2.0                  1.46 ± 0.38
  Lung                                  2.4                                              0.58                                                 5.5 ± 0.5                                                        5.7                  
  Muscle                                2.2                                              0.74                                                 0.8 ± 0.1                                                                             1.35 ± 0.31
  Pancreas                              3.9                                              0.65                                                                                                                                       
  Red blood cells                       1.1                                              0.65                                                                                                                                       
  Skin                                  5.7                                              0.69                                                                                                                                       
  Spleen                                1.0                                              0.55                                                 2.8 ± 0.8                                                        2.9                  

The age-specific partition coefficient is the product of the ratio of unbound fractions and the partition coefficient.

*Ex vivo* exposure (mean ± SD) of 4--5 g of cut-up human tissue to BPA over 6 hr in a flask; *n* = 3--4.

BPA exposure to rats via multiple intravenous infusions, with tissues taken at around 3.5 hr (*n* = 2 rats) and 4.5 hr (*n* = 2 rats) after dose initiation.

###### 

Permeability × surface area (PS) products (L/min) for BPA and BPA-Glu for adults.

                      BPA      BPA-Glu                  
  ------------------- -------- --------- -------------- --------------
  Venous/arterial              1,675                    0.018
  Adipose             4,725    648       0.051          6.9 × 10^−3^
  Bone                4,766    973       0.051          0.010
  Brain               0.51     142       5.4 × 10^−6^   1.5 × 10^−3^
  Gonads              82       5.7       8.9 × 10^−4^   5.7 × 10^−5^
  Heart               3,123    142       0.033          1.5 × 10^−3^
  Kidneys             14,427   244       1.2            2.6 × 10^−3^
  Large intestine     5,145    24        0.83           2.6 × 10^−3^
  Liver               25,389   971       0.27           0.010
  Lung                59       1,819     6.3 × 10^−4^   0.019
  Muscle              2,752    1,959     0.029          0.020
  Pancreas            16,529   92        2.3            9.9 × 10^−4^
  Portal vein blood            2,513                    0.027
  Skin                17       419       1.9 × 10^−4^   4.5 × 10^−3^
  Small intestine     18,116   42        1.3            4.5 × 10^−4^
  Spleen              60,468   195       2.8            2.1 × 10^−3^
  Stomach             24,035   13        2.4            1.4 × 10^−4^

rbc, red blood cells.
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